Covid-19 man­u­fac­tur­ing roundup: Catal­ent, As­traZeneca de­fend vac­cine batch qual­i­ty in safe­ty row — FT; US buys more Covid-19 an­ti­body sup­plies

As­traZeneca and key man­u­fac­tur­ing part­ner Catal­ent are de­fend­ing the qual­i­ty of the Covid-19 vac­cine be­ing dis­trib­uted in Eu­rope, re­ports the Fi­nan­cial Times.

The British drug­mak­er says it’s un­like­ly that any prob­lems with their vac­cine batch­es are re­spon­si­ble for the re­cent re­ports of blood clots among peo­ple get­ting the jab. But Emer Cooke, the head of EMA, said on Tues­day that the agency was in­ves­ti­gat­ing “the pos­si­bil­i­ty or plau­si­bil­i­ty of any events linked to spe­cif­ic batch­es” of the Ox­ford/As­traZeneca jab, as well as “any dif­fer­ences in man­u­fac­tur­ing . . . that might lead to some dis­par­i­ties across batch­es.”

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER